种族/民族与21基因复发评分及乳腺癌特异性死亡率的关联
IMPORTANCE: Given the widespread use of the 21-gene recurrence score for identifying candidates for adjuvant chemotherapy, it is important to examine the performance of the Oncotype DX Breast Recurrence Score test in diverse patient populations to validate this approach for tailo…
要点
- 黑人女性复发评分>25的比例显著高于非西班牙裔白人(17.7% vs 13.7%,P<.001)。
- 腋窝淋巴结阴性者中,各复发评分层内黑人女性乳腺癌特异性死亡率均高于非西班牙裔白人。
- 21基因复发评分在黑人女性中的预后准确性较低(C指数0.656 vs 0.700,P=.002)。
核心结论
- 在美国,黑人女性较非西班牙裔白人更常见高风险复发评分,且在校正年龄、肿瘤特征和治疗后,相同复发评分下腋窝淋巴结阴性乳腺癌特异性死亡率更高。
- Oncotype DX乳腺癌复发评分测试在黑人女性中的预后准确性较低,提示用于筛选辅助化疗候选者的基因组检测可能需要在种族/民族多样性更高的人群中进行模型校准。
研究设计与样本
- 回顾性、基于人群的队列研究,使用SEER Oncotype DX 2004-2015数据库。
主要发现
- 黑人女性复发评分>25的比例显著高于非西班牙裔白人(17.7% vs 13.7%;P < .001)。
- 在腋窝淋巴结阴性肿瘤女性中,经年龄、肿瘤特征和治疗校正的竞争风险模型显示,每个复发评分风险层内黑人女性的乳腺癌特异性死亡率均高于非西班牙裔白人:复发评分0-10的亚分布风险比为2.54(95% CI,1.44-4.50),11-25为1.64(95% CI,1.23-2.18),>25为1.48(95% CI,1.10-1.98)。
- 复发评分的预后准确性在黑人女性中显著较低,C指数为0.656(95% CI,0.592-0.720),而非西班牙裔白人为0.700(95% CI,0.677-0.722)(P = .002)。
临床怎么用
- 临床解读Oncotype DX复发评分时应考虑种族/民族差异,黑人女性相同评分下乳腺癌特异性死亡风险更高。
- 对于黑人女性,21基因复发评分预后准确性较低,辅助化疗决策需综合其他临床病理因素。
- 基因组检测用于筛选辅助化疗候选者时,可能需要在种族/民族多样性更高的人群中进行模型校准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Given the widespread use of the 21-gene recurrence score for identifying candidates for adjuvant chemotherapy, it is important to examine the performance of the Oncotype DX Breast Recurrence Score test in diverse patient populations to validate this approach for tailoring treatment in women in racial/ethnic minority groups. OBJECTIVE: To examine whether breast cancer-specific mortality for women with hormone-dependent breast cancer differs by race/ethnicity across risk categories defined by the Oncotype DX Breast Recurrence Score test and whether the prognostic accuracy of the 21-gene recurrence score differs by race/ethnicity. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, population-based cohort study used the Surveillance, Epidemiology, and End Results Oncotype DX 2004-2015 database to obtain breast cancer-specific survival data on US women 18 years and older who were diagnosed with first primary stage I to III, estrogen receptor-positive breast cancer between January 1, 2004, and December 31, 2015, and had tumor testing through the Genomic Health Clinical Laboratory. Data were analyzed from April 20 to September 27, 2020. MAIN OUTCOMES AND MEASURES: The primary outcome was breast cancer-specific mortality among women from different racial/ethnic groups stratified by the 21-gene recurrence score risk categories. Secondary analyses compared the prognostic accuracy of the recurrence score among the different racial/ethnic groups. RESULTS: A total of 86 033 patients with breast cancer (mean [SD] age, 57.6 [10.6] years) with Oncotype DX Breast Recurrence Score test information were available for the analysis, including 64 069 non-Hispanic White women (74.4%), 6719 non-Hispanic Black women (7.8%), 7944 Hispanic women (9.2%), 6950 Asian/Pacific Islander women (8.0%), and 351 American Indian/Alaska Native women (0.4%). Black women were significantly more likely than non-Hispanic White women to have a recurrence score greater than 25 (17.7% vs 13.7%; P < .001). Among women with axillary node-negative tumors, competing risk models adjusted for age, tumor characteristics, and treatment found higher breast cancer-specific mortality for Black compared with non-Hispanic White women within each recurrence score risk stratum, with subdistribution hazard ratios of 2.54 (95% CI, 1.44-4.50) for Black women with recurrence scores of 0 to 10, 1.64 (95% CI, 1.23-2.18) for Black women with recurrence scores of 11 to 25, and 1.48 (95% CI, 1.10-1.98) for Black women with scores greater than 25. The prognostic accuracy of the recurrence score was significantly lower for Black women, with a C index of 0.656 (95% CI, 0.592-0.720) compared with 0.700 (95% CI, 0.677-0.722) (P = .002) for non-Hispanic Whites. CONCLUSIONS AND RELEVANCE: In this cohort study, Black women in the US were more likely to have a high-risk recurrence score and to die of axillary node-negative breast cancer compared with non-Hispanic White women with comparable recurrence scores. The Oncotype DX Breast Recurrence Score test has lower prognostic accuracy in Black women, suggesting that genomic assays used to identify candidates for adjuvant chemotherapy may require model calibration in populations with greater racial/ethnic diversity.
引用
- Hoskins KF, Danciu OC, Ko NY, et al. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women. JAMA Oncol. 2021. PMID: 33475714. doi:10.1001/jamaoncol.2020.7320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。